The Harvard spin-out disrupting drug discovery

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rani Powers, Founder & CEO at Pluto Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering:

• Her passion for coding and what drew her into the world of biology
• How the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-up
• The value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologists
• Spinning out her company from the Wyss Institute at Harvard University... in a non-conventional way
• How the adoption and implementation of AI is just getting started... and how it will evolve

Dr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster.

She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.